Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CME Stock Forecast 2026-2027
$287.65
Current Price
$104.29B
Market Cap
Buy 6
Hold 6
Sell 4
Wall St Analyst Ratings
Distance to CME Price Targets
+25.8%
To High Target of $362.00
+11.2%
To Median Target of $320.00
-16.2%
To Low Target of $241.00
CME Price Momentum
-3.2%
1 Week Change
-6.4%
1 Month Change
+10.5%
1 Year Change
+5.3%
Year-to-Date Change
-12.6%
From 52W High of $329.16
+14.2%
From 52W Low of $251.90
📊 TOP ANALYST CALLS
Did CME Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CME Group is one of their latest high-conviction picks.
Latest CME Stock Price Targets & Analyst Predictions
Based on our analysis of 31 Wall Street analysts, CME has a neutral consensus with a median price target of $320.00 (ranging from $241.00 to $362.00). The overall analyst rating is Buy (6.5/10). Currently trading at $287.65, the median forecast implies a 11.2% upside. This outlook is supported by 6 Buy, 6 Hold, and 4 Sell ratings.
The most optimistic forecast comes from Michael Cyprys at Morgan Stanley, projecting a 25.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CME Analyst Ratings
6
Buy
6
Hold
4
Sell
CME Price Target Range
Low
$241.00
Average
$320.00
High
$362.00
Current: $287.65
Latest CME Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CME.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 15, 2026 | Piper Sandler | Patrick Moley | Overweight | Maintains | $329.00 |
| Apr 13, 2026 | Barclays | Benjamin Budish | Equal-Weight | Maintains | $343.00 |
| Apr 10, 2026 | Morgan Stanley | Michael Cyprys | Overweight | Maintains | $362.00 |
| Apr 8, 2026 | Barclays | Benjamin Budish | Equal-Weight | Maintains | $344.00 |
| Apr 8, 2026 | Keefe, Bruyette & Woods | Chris Allen | Market Perform | Reinstates | $305.00 |
| Mar 4, 2026 | Argus Research | Stephen Biggar | Hold | Downgrade | $N/A |
| Feb 5, 2026 | JP Morgan | Kenneth Worthington | Underweight | Maintains | $266.00 |
| Feb 5, 2026 | TD Cowen | Bill Katz | Buy | Maintains | $328.00 |
| Feb 5, 2026 | Morgan Stanley | Michael Cyprys | Overweight | Maintains | $340.00 |
| Feb 5, 2026 | RBC Capital | Ashish Sabadra | Sector Perform | Maintains | $302.00 |
| Feb 5, 2026 | Barclays | Benjamin Budish | Equal-Weight | Maintains | $312.00 |
| Jan 15, 2026 | Morgan Stanley | Michael Cyprys | Overweight | Maintains | $319.00 |
| Jan 14, 2026 | TD Cowen | Bill Katz | Buy | Upgrade | $305.00 |
| Dec 22, 2025 | Morgan Stanley | Michael Cyprys | Overweight | Maintains | $320.00 |
| Dec 12, 2025 | Barclays | Benjamin Budish | Equal-Weight | Maintains | $304.00 |
| Nov 13, 2025 | Piper Sandler | Patrick Moley | Overweight | Maintains | $313.00 |
| Oct 23, 2025 | Morgan Stanley | Patrick Moley | Overweight | Maintains | $314.00 |
| Oct 23, 2025 | Deutsche Bank | Brian Bedell | Buy | Upgrade | $300.00 |
| Oct 23, 2025 | UBS | Alex Kramm | Neutral | Maintains | $280.00 |
| Oct 13, 2025 | Raymond James | Patrick O'Shaughnessy | Outperform | Maintains | $307.00 |
CME Group Inc. (CME) Competitors
The following stocks are similar to CME Group based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CME Group Inc. (CME) Financial Data
CME Group Inc. has a market capitalization of $104.29B with a P/E ratio of 25.8x. The company generates $6.51B in trailing twelve-month revenue with a 62.6% profit margin.
Revenue growth is +8.0% quarter-over-quarter, while maintaining an operating margin of +63.8% and return on equity of +14.8%.
Valuation Metrics
Market Cap
$104.29B
Enterprise Value
$102.37B
P/E Ratio
25.8x
PEG Ratio
0.7x
Price/Sales
16.0x
Growth & Margins
Revenue Growth (YoY)
+8.0%
Gross Margin
+85.4%
Operating Margin
+63.8%
Net Margin
+62.6%
EPS Growth
+35.3%
Financial Health
Cash/Price Ratio
+4.4%
Current Ratio
1.0x
Debt/Equity
13.1x
ROE
+14.8%
ROA
+1.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
CME Group Inc. (CME) Business Model
About CME Group Inc.
What They Do
Operates a leading derivatives marketplace.
Business Model
The company generates revenue primarily through clearing and settlement services, transaction fees, and market data provision. By offering a wide range of futures and options contracts across various asset classes, CME Group allows market participants to manage risk effectively and facilitates high liquidity and electronic trading.
Additional Information
CME Group, founded in 1898 and headquartered in Chicago, operates under well-known brands like CME, CBOT, and NYMEX. It serves a diverse clientele including professional traders, financial institutions, and governments, and plays a critical role in establishing benchmark prices and ensuring market integrity globally.
Company Information
Sector
Financial Services
Industry
Financial Data & Stock Exchanges
Employees
3,875
CEO
Mr. Terrence A. Duffy
Country
United States
IPO Year
2002
Website
www.cmegroup.comCME Group Inc. (CME) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Nasdaq (NDAQ) Reports Next Week: Wall Street Expects Earnings Growth
Nasdaq (NDAQ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 16, 2026
By Zacks Equity Research
Tale of the Tape
CME Group (CME) Earnings Expected to Grow: Should You Buy?
CME (CME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 15, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
ESMA Recognizes CME Group Benchmark Administration as a Third-Country Benchmark Administrator
4 days ago
Quick Summary
CME Group's Benchmark Administration has been recognized by ESMA as a third-country benchmark administrator, enhancing the usage of CME Term SOFR Reference Rates in Europe.
Why It Matters
CME Group's recognition by ESMA enhances its credibility and market presence in Europe, potentially increasing trading volumes and attracting more investors to its benchmark products.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
DTCC and CME Group's expanded cross-margining arrangement, approved by the SEC and CFTC, will enhance capital efficiencies for clients starting April 30, 2026.
Why It Matters
The new cross-margining arrangement enhances capital efficiency for market participants, potentially reducing costs and improving liquidity, which can positively impact trading volumes and profitability.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CME's performance for Q1 2026 will be assessed through key metrics rather than just traditional revenue and earnings estimates.
Why It Matters
CME's expected performance metrics can reveal underlying trends and risks, affecting stock valuation and investment strategies for the upcoming quarter.
Source: Zacks Investment Research
Market Sentiment:
Neutral
CME Group to Expand Equity Index Dividend Suite with New Mid-Curve Options and Quarterly Futures
5 days ago
Quick Summary
CME Group plans to expand its Equity Index Dividend suite on May 11, adding Mid-curve options on S&P 500 Annual Dividend Index futures and Nasdaq-100 and Russell 2000 Quarterly Dividend Index futures, pending regulatory review.
Why It Matters
CME Group's expansion of its Equity Index Dividend suite enhances options for managing dividend exposure, crucial in a volatile interest rate environment, impacting investment strategies and risk management.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CME Group receives a strong buy rating due to solid fundamentals, technical factors, sustainable dividend growth, strong margins, and low leverage, despite a neutral consensus among analysts.
Why It Matters
CME Group's strong buy rating reflects solid fundamentals, growth potential, and sustainable dividends, signaling stability and attractiveness for long-term investment amid mixed market sentiment.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
CME is expected to report earnings that may exceed forecasts due to favorable conditions. Investors should prepare for the upcoming earnings report.
Why It Matters
CME's potential for an earnings beat indicates strong financial performance, likely boosting investor confidence and potentially driving stock prices higher.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About CME Stock
What is CME Group Inc.'s (CME) stock forecast for 2026?
Based on our analysis of 31 Wall Street analysts, CME Group Inc. (CME) has a median price target of $320.00. The highest price target is $362.00 and the lowest is $241.00.
Is CME stock a good investment in 2026?
According to current analyst ratings, CME has 6 Buy ratings, 6 Hold ratings, and 4 Sell ratings. The stock is currently trading at $287.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CME stock?
Wall Street analysts predict CME stock could reach $320.00 in the next 12 months. This represents a 11.2% increase from the current price of $287.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CME Group Inc.'s business model?
The company generates revenue primarily through clearing and settlement services, transaction fees, and market data provision. By offering a wide range of futures and options contracts across various asset classes, CME Group allows market participants to manage risk effectively and facilitates high liquidity and electronic trading.
What is the highest forecasted price for CME CME Group Inc.?
The highest price target for CME is $362.00 from Michael Cyprys at Morgan Stanley, which represents a 25.8% increase from the current price of $287.65.
What is the lowest forecasted price for CME CME Group Inc.?
The lowest price target for CME is $241.00 from at , which represents a -16.2% decrease from the current price of $287.65.
What is the overall CME consensus from analysts for CME Group Inc.?
The overall analyst consensus for CME is neutral. Out of 31 Wall Street analysts, 6 rate it as Buy, 6 as Hold, and 4 as Sell, with a median price target of $320.00.
How accurate are CME stock price projections?
Stock price projections, including those for CME Group Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 2:07 AM UTC